Preferred Label : Parkinson's Disease Pathway KEGG;
NCIt synonyms : Parkinsons Disease Pathway;
NCIt related terms : Parkinson's Disease;
Alternative definition : KEGG: Parkinson's disease (PD) is a progressive neurodegenerative movement disorder
that results primarily from the death of dopaminergic neurons in the substantia nigra.
Mutations in alpha-synuclein, UCHL1 (ubiquitin carboxy-terminal hydrolase L1), parkin,
DJ1 (a parkin-associated protein involved with oxidative stress), and PINK1 (a putative
serine threonine kinase) are known to cause early-onset PD. Mutations or altered expression
of these proteins contributes to PD pathogenesis through common mechanisms that result
in proteasome dysfunction, mitochondrial impairment, and oxidative stress. Point mutations
in alpha-synuclein and the recently described functional duplication of alpha-synuclein
lead to excessive intracellular accumulation and protofibril formation. Decrease in
the amount of soluble alpha-synuclein tends to increase free cytoplasmic dopamine
and the formation of reactive oxygen species (ROS). Indeed, formation of protofibrils
or aggregates and Lewy bodies (LBs) diminishes the availability of the physiological
forms of alpha-synuclein, favoring an increase in TH (tyrosine hydroxylase) and DAT
(dopamine transporter), but diminishes formation of vesicles and neuronal plasticity.
Modification of parkin and UCHL1 are associated with the ubiquitin-proteasome system
pathway and may increase proteotoxic stress. Mutations in parkin, DJ1, and PINK1 may
alter mitochondrial activity, potentially impairing proteasomal function. Environmental
toxins such as N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone can
cause mitochondrial dysfunction and oxidative stress.;
NCIt note : This pathway originally was KEGG_ID hsa05020.;
KEGG ID : hsa05012;
Origin ID : C38845;
UMLS CUI : C1521736;
Automatic exact mappings (from CISMeF team)
Semantic type(s)
has_gene_product_element
pathway_has_gene_element
https://www.acadpharm.org/publications/page.php?rb1=50&id_doc=7184
2024
France
scientific and technical information
parkinson's disease, nos
Intensity and Distress 1
One
Fear Score 1
Histone-Lysine N-Methyltransferase EHMT1
CDISC SDTM Model Version 1.5
Agreement Score 1
Thought Score 1
Symptoms Extent Score 1
Guadeloupe
Phase I Trial
Upset Score 1
Glucagon-Like Peptide-1 Receptor
Severity of Symptom Score 1
Mild Adverse Event
One Hundred Percent
One Full Term Pregnancy
Illness Intrusiveness Rating 1
Parkinson's Disease Pathway KEGG
glucagon-like peptide 1
Never Smoker
Parkinson Disease
Gleason Grade Group 1
ECOG Performance Status 1
Receptor
Neck Pain Score 1
What Month is it
1+ Score, WHO
1+ Score
CDISC SDTM Model Version 1.6
Tumor Regression Score 1
Clinical Status Ordinal Scale Outcome 1
parkinson disease
---
https://minerva-ebp.be/FR/Analysis/857
2024
Belgium
critical appraisal or critical reading
Effect, Appearance
Parkinson's Disease Pathway KEGG
Preventive Intervention
parkinson's disease, nos
Outcome of Therapy
What Month is it
parkinson disease
persons
accidental falls
No Effect
Parkinson Disease
People
disease
---
https://minerva-ebp.be/FR/Analysis/847
2023
Belgium
critical appraisal or critical reading
disease
Pet is as Active as it Has Been
parkinson's disease, nos
Used Quit Cigarette Smoking Videos
Balanced Translocation
has patient
What Month is it
postural balance
Parkinson Disease
Active Control
video games
Enhance
Active License
Active State
Balance
parkinson disease
patients
mobility, nos
Range of Motion
Questionnaire Not Completed Due to Patient Illness
Mobility Ability
Improved
Splayed
Parkinson's Disease Pathway KEGG
---